President Donald Trump signed an executive order on April 18 directing the FDA and DEA to create accelerated pathways for psychedelic therapies including ibogaine, psilocybin, LSD, and MDMA. The order allocates $50 million through ARPA-H to match state investments in psychedelic research targeting PTSD, depression, and addiction, with particular emphasis on treating veterans. FDA Commissioner Dr. Marty Makary said drugs could now get approved "in weeks, not a year or more."

Trump signed the order alongside Health Secretary RFK Jr., CMS Administrator Dr. Oz, and podcaster Joe Rogan, who Trump credited with pushing for the initiative. "In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness," Trump said. The order also invokes the Right to Try Act to give eligible patients access to investigational psychedelic drugs still under FDA review.

Experts have raised safety concerns, noting that ibogaine lacks FDA approval, remains Schedule I, and carries risks of fatal cardiac arrhythmias. Critics worry the administration may bypass rigorous clinical trial standards. Psilocybin currently has stronger clinical evidence for depression treatment than ibogaine.